Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Biotech Movers: Lantheus Holdings Inc (LNTH) and Achillion Pharmaceuticals, Inc. (ACHN)

As we noted last week, the close of the third quarter and the start of the final quarter of the year is when volume really starts to pick up in wider financial asset markets, and there are no markets where this is more apparent than the biotech space. News and data driven catalysts come and go, but if there’s volume behind them, they can have a sustained impact on the medium term directional bias of the companies to which they relate.

Here are two companies that have moved over the last few days, and a look at what’s driving the action in both – Lantheus Holdings Inc (NASDAQ:LNTH) and Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN).

biotech, shares, market, amgen, percent, technical, economy, pharmaceutical, rate, quote, producer, drag, business, bio, capitalization, tech, biotechnology, sector, gain,,

g0d4ather/Shutterstock.com

Let’s kick things off with Lantheus Holdings Inc (NASDAQ:LNTH). On Friday, the company announced an offering that will see if issue 5.2 million shared of common stock to Credit Suisse and Jefferies, as part of an underwritten public offering. The issue is pursuant to a shelf offering, so it’s been a while coming, but markets have still reacted negatively to the volume of shares on offer, and in turn, the dilutive impact this will have on shareholders’ current holdings.

At Friday market open in the US, the company traded just off annual highs for a little over $9.4 a share. By market close, the company went for two dollars lower, $7.44, having fallen close to 22% on the session.

For those not familiar with the company, Lantheus Holdings Inc (NASDAQ:LNTH) is a medical device and imaging company (Lantheus Holdings is parent to its client facing brand, Lantheus Medical Imaging, Inc) based out of Massachusetts. The company has a current market cap of $250-300 million, and generates within this range in annual revenues, which at a glance makes it look cheap at current prices. However, a look at the balance sheet somewhat negates this bias. The company has juts shy of $350 million long term debt on its books, and this weighs heavily on its potential to generate an income, despite its reasonable revenues figures.

The raise is going to go towards paying down some principal on its senior secured credit facilities, which is basically a black hole from a shareholder perspective (it will loosen the interest burden a bit but far from offset the dilution) and that’s why the company is selling off to the extent it has.

Follow Lantheus Holdings Inc. (NASDAQ:LNTH)
Trade (NASDAQ:LNTH) Now!

Moving on, let’s look at Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN).

Achillion has had a pretty rough few weeks, and is down nearly 15% on August highs, However, the company just put out data relating to a phase IIa trial of its lead hepatitis C candidate, and looks set for a certain level of reprieve on the back of the numbers. The trial setup is pretty convoluted, based on the fact that Achillion out licensed the development and commercialization to Johnson & Johnson (NYSE:JNJ). A company called Alios BioPharma is conducting the trial, with the latter being a sub of Janssen, which in turn is a sub of J&J.

Two of the drugs in the trial are Achillion’s, and the third is simeprevir, an already approved Hep C SOC. The data showed that all the patients receiving a triple combo dose of all three drugs remained HCV RNA undetectable 24 weeks after completing therapy. The drugs under scrutiny didn’t add any safety or tolerability concerns onto the current regimen, and while it’s still early days, the combo looks like a shoo-in for an easy phase III and, beyond, a successful application with the agency.

We should see the full release as part of a presentation set to take place at the European Association for the Study of the Liver (EASL) Special Conference, in Paris, France, on September 23-24. Chances are we will see some further upside on this presentation, as the numbers draw speculative volume towards Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) in anticipation of a momentum play.

Another one to watch closely going forward.

Follow Achillion Pharmaceuticals Inc (NASDAQ:ACHN)
Trade (NASDAQ:ACHN) Now!

Note: This article is written by Mark Collins and was originally published at Market Exclusive.

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!